1 of 2
Matt JenningsMatt Jennings, president and CEO of Phillips-Medisize Corporation, says the manufacturing sites to be acquired are "to Switzerland standards” and so operations will be integrated "rapidly and seamlessly" into Phillips-Medisize.
2 of 2
Medtec vlog day 2—Netstal clarifies brand's outlook under KraussMaffei, Phillips-Medisize and Asia
Sam Anson's vlog of day 2 at Medtec Europe. Contents and interviewees include: Dr Patrick Blessing, head of Medical at Netstal, who reassures Netstal customers that the company will not be swallowed up by KraussMaffei; Andrew Sargisson of Kebo whose mould was in operation on the Netstal machine on show; Willem van den Bruinhorst, European president of Phillips-Medisize on how a high speed high volume automated medical device manufacturing line might look in 10-15 years; Christoph Lhota, head of medical at Engel, on the task of building entire factories for customers in developing countries; Aaron Johnson of Accumold on balancing the relationship between regulation and innovation; Lisa Vickers of Putnam Plastics on extruding ever more demanding and exacting requirements; Nicholas Wisniewski of Qosina on components made from alternatives to polycarbonate and PVC; and Martin Day of Carclo Diagnostics on new plastic technologies for microfluidic-based point of care diagnostic devices.
Finished medical device outsourcing company Phillips-Medisize has announced that it has entered into a definitive agreement with the Adval Tech Group to purchase, for an undisclosed amount, two manufacturing operations in Suzhou, China (Adval Tech Medical (Suzhou) Co. Ltd.) and Queretaro, Mexico (Omni Manufacturing Services S.A. de C. V.). The transaction is expected to close subject to receipt of final regulatory approvals.
The Suzhou, China medical technology facility is both ISO9001 and ISO13485 compliant and SFDA certified to manufacture finished drug delivery systems and related medical devices. The Queretaro, Mexico facility is also both ISO9001 and ISO13485 compliant and FDA registered to manufacture components and subassemblies, drug delivery systems and other related medical devices. The Mexico facility is also manufacturing injection moulded components and decorative components for automotive and consumer applications.
Phillips-Medisize plans to retain all approximately 350 employees from both operations, which will ensure continuity for all existing customers of these operations. This will also position Phillips-Medisize to begin servicing its global customer base from these locations immediately.
Matt Jennings, president and CEO of Phillips-Medisize Corporation, said, “We are very pleased to welcome the China and Mexico employees to the Phillips-Medisize team. This acquisition reflects continued successful execution of our strategic acquisition growth strategy to offer our customers a global manufacturing and designing standard while providing local production and development capabilities. Because these facilities are state-of-the-art manufacturing sites to Switzerland standards, in China and Mexico, we expect these operations will integrate rapidly and seamlessly into Phillips-Medisize and be available immediately to support our global customers.”